TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01671735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
Study: NCT03774173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
Study: NCT04074473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propranolol
Description: Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal varice ligation
Description: Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DC propranolol
Description: Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
Study: NCT03325452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: venous lactate
Description: value of venous lactate
Study: NCT01462552

Intervention type: DRUG
Intervention: Lapatanib
Description: Prescription of lapatinib (Tykerb)

Intervention type: DRUG
Intervention: Lapatanib
Description: Prescription of lapatinib (Tykerb)
Study: NCT03423589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
Study: NCT02228031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
Study: NCT01949207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLA
Description: Endovenous laser ablation of great saphenous vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLA
Description: Endovenous laser ablation of great saphenous vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phlebectomies
Description: removal of incompetent veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phlebectomies
Description: removal of incompetent veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRansluminal Occlusion of Perforators (TRLOP)
Description: TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
Study: NCT03044431

Intervention type: PROCEDURE
Intervention: Cell therapy
Description: Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
Study: NCT01517568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide [3H]
Description: A single dose of 0.75 mg will be given as a subcutaneous injection
Study: NCT00618475

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: 10 sessions~1 hour per week
Study: NCT03845608

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pulmonary Recruitment Maneuver
Description: Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pulmonary Recruitment Maneuver
Description: Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
Study: NCT03724968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given by vein on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given by vein on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab will be given by vein on day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
Study: NCT02043561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of urge by rectal distension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of urge by rectal distension

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: induction of urge by rectal distension
Study: NCT00000318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 1. Experimental Maintenance treatment with daily medication~2. Experimental Maintenance treatment with thrice-weekly medication
Study: NCT03275441

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroretinography
Description: An additional electroretinogram performed after 10 minutes of dark adaptation.
Study: NCT04044820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Prescription
Description: Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion.
Study: NCT03255785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract surgery plus one iStent and one iStent Supra implanted
Description: Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
Study: NCT02205476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06473871
Description: Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06473871
Description: Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
Study: NCT03708744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: M207 3.8mg, 30 min, upper arm
Description: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: M207 3.8mg, 30 min, upper arm
Description: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: M207 3.8mg, 30 min, upper arm
Description: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A: M207 3.8mg, 30 min, upper arm
Description: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
Study: NCT04414644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Condition
Description: Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Condition
Description: Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
Study: NCT02509624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: 6 mg tablets administered orally in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: 6 mg tablets administered orally in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: 6 mg tablets administered orally in fed state
Study: NCT03499158

Intervention type: OTHER
Intervention: nerve conduction study
Description: nerve conduction study

Intervention type: OTHER
Intervention: nerve conduction study
Description: nerve conduction study
Study: NCT03708744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: M207 3.8 mg, 30 min, thigh
Description: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: M207 3.8 mg, 30 min, thigh
Description: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Study: NCT02536508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI 14.4/9.6 μg
Description: Glycopyrronium and Formoterol Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Description: Budesonide and Formoterol Fumarate
Study: NCT02613481

Intervention type: DRUG
Group type: OTHER
Intervention: Poly-L-Lactic Acid (Sculptra) injection
Description: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
Study: NCT04026100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTA101
Description: Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10\^6), medium dose (2×10\^6), and high dose (3×10\^6).
Study: NCT02348216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
Study: NCT04046887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonsurf
Description: Lonsurf will be administered orally twice a day on days 2-6 and 16-20 of every 28-day cycle at a dose of 25 mg/m2, 20 mg/m2 or 30 mg/m2 depending on cohort assignment.
Study: NCT03554642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkbot
Description: Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
Study: NCT02917356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spiritual laying on of hands (SP)
Description: The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-spiritual Laying on of Hands
Description: The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind.
Study: NCT03262545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
Study: NCT04046887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 800 mg/m2, 600 mg/m2 or 1000 mg/m2 depending on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 100 mg/m2, 75 mg/m2 or 125 mg/m2 depending on cohort assignment.
Study: NCT05087511

Intervention type: OTHER
Intervention: motor and sensory development assessment
Description: Peabody Motor Development Scale 2 was used to evaluate motor development and Dunn's Sensory Profile was used to evaluate sensory processing.

Intervention type: OTHER
Intervention: motor and sensory development assessment
Description: Peabody Motor Development Scale 2 was used to evaluate motor development and Dunn's Sensory Profile was used to evaluate sensory processing.
Study: NCT03262545

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Physical properties of placebos are consistent with apatinib
Study: NCT02348216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert
Study: NCT03312725

Intervention type: DEVICE
Intervention: WEB aneurysm embolization system
Description: The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
Study: NCT03820778

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body MRI
Description: WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)
Study: NCT02237118

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel One

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel One

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UrgoTul
Study: NCT00616265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Pressure device on airway to maintain it open
Study: NCT02237118

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UrgoTul
Study: NCT01066273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-Stim
Description: The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
Study: NCT04178902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-467
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-467
Description: Intravenous (IV) Infusion
Study: NCT03441412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: 2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated.
Study: NCT03860519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Medication Monitors on ICS and SABA - Active Mode
Description: The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Medication Monitors on ICS and SABA - Silent Mode
Description: The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma App Tracking of ICS/SABA Usage - Active Mode
Description: Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma App Tracking of ICS/SABA Usage - Silent Mode
Description: Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
Study: NCT03441412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated.